Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set an "overweight" rating and a $74.00 price target on the stock. Cantor Fitzgerald's target price indicates a potential upside of 106.30% from the company's current price.

Other research analysts have also issued research reports about the stock. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Piper Sandler restated an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Chardan Capital began coverage on Monopar Therapeutics in a research report on Monday, June 23rd. They issued a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Monopar Therapeutics Stock Performance

NASDAQ MNPR opened at $35.87 on Monday. The firm's 50 day moving average price is $35.99 and its two-hundred day moving average price is $35.18. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30. The stock has a market cap of $219.52 million, a price-to-earnings ratio of -10.31 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. On average, research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MNPR. JPMorgan Chase & Co. bought a new position in Monopar Therapeutics in the fourth quarter worth $45,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics during the 4th quarter worth about $11,247,000. Geode Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after acquiring an additional 24,530 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $23,435,000. Finally, Gerber LLC bought a new stake in Monopar Therapeutics in the first quarter valued at about $204,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.